Drug intelligence / Profile preview

interferon alpha-2a + donepezil

Development stage: Discontinued
Lead developer: Eisai
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

Interferon alpha-2a + donepezil is an investigational combination therapy studied for the treatment of mild to moderate Alzheimer's disease. The regimen consists of human recombinant interferon alpha-2a (hrIFN-a), a cytokine typically used for its antiviral and antineoplastic properties, administered orally (ingested) alongside the standard-of-care acetylcholinesterase inhibitor donepezil (Aricept). The National Center for Research Resources (NCRR) sponsored a Phase I/II clinical trial (NCT00031018) to evaluate whether low-dose ingested interferon alpha could modulate neuroinflammation by decreasing acute-phase reactants and pro-inflammatory cytokines like interleukin-6 (IL-6), thereby slowing cognitive decline. While interferon alpha-2a is well-established in other therapeutic areas, its development for Alzheimer's disease has not progressed beyond early-phase clinical investigation.

Brand names: Roferon-A + Aricept
Other names: Ingested interferon alpha-2a + donepezilOral interferon alpha-2a + donepezilhrIFN-alpha2a + donepezil

Targets

IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)Acetylcholinesterase

Beyond the preview

Go deeper on interferon alpha-2a + donepezil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alpha-2a + donepezil.

Explore the full profile